North Bergen, New Jersey--(Newsfile Corp. - January 7, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), announces that the Letter of Intent between the Company and Revive Regenerative, Inc., dated September 12, 2025, (the "LOI") has expired and it no longer in effect.To view an enhanced version of this graphic, please visit:https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/n_image_a4b47bafbc19ca58a81daa5f3a4e1fb8.jpgThe LOI contained a proposed closing date of October ...

PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today announced that its BioDefense Inc. Burn Pit Initiative has received regulatory approval to proceed, marking a significant milestone in the Company’s mission to address the long-term health consequences of toxic burn pit exposure among U.S. military veterans. ...

FSdC demonstrated statistically significant and superior improvement in disc preservation and structural integrity compared to other treatmentsHOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced positive preclinical results for FSdC ...

Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the initiation of a rolling submission of a Biologics License Application (BLA) to the Food and Drug Admini ...

Milestone advances manufacturing readiness and supports long-term commercialization strategyBURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. The extended shelf life is validated by ongoing stabi ...

Reducing inflammation helps create a regenerative environment in the Central Nervous SystemTORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory data demonstrating that its proprietary exosomes can significantly reduce inflammatory activity compared to untreated cells and cells treated with a commercially available exosome product. “Inflammation and regeneration are conflicting bi ...

Core Insights - Creative Medical Technology Holdings, Inc. has successfully completed patient enrollment in its FDA-cleared ADAPT clinical trial for CELZ-201, a non-opioid therapy for chronic lower back pain [1][3][4] - The completion of enrollment marks a significant milestone, transitioning the trial into follow-up and data analysis phases, with expectations of generating meaningful clinical data [3][4][8] - CELZ-201 is positioned to address a large, underserved market, with chronic lower back pain affecting over 16 million Americans and representing a multi-billion-dollar market [3][6] Company Developments - The ADAPT trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and preliminary efficacy of CELZ-201 [5] - The trial has received a positive safety review from an independent Data Safety Monitoring Board, confirming a favorable safety profile for CELZ-201 [2][5] - The company’s StemSpine® intellectual property portfolio enhances its strategic position as it moves toward later-stage clinical development and potential commercialization [7] Future Outlook - Following enrollment completion, the company plans to continue scheduled DSMB reviews, advance toward topline safety and efficacy readouts, and evaluate strategic pathways for late-stage development and commercialization [9][10] - Management emphasizes a results-driven phase, focusing on executing flawlessly and generating compelling data to unlock the full value of CELZ-201 for patients and shareholders [10]

Winter Park, Florida--(Newsfile Corp. - December 15, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med subsidiary, today announced that the independent Institutional Review Board (IRB) BeyondBound has approved the company's patent-pending clinical study protocol focused on Autism Spectrum Disorder (ASD).IRB Approval EmailTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/278050_adia_irb_approved_screenshot.jp ...

Industry Overview - The MedTech industry faced significant uncertainties in 2025 due to shifting trade policies, reduced federal funding, and supply-chain disruptions, yet it generated $584 billion in revenues, marking seven consecutive years of growth [1][2] - M&A activity in the industry shifted towards fewer but larger deals, with the average transaction size increasing by 11% from 2024 [2] - Rapid technological advancements, particularly in AI and data science, are reshaping the industry, with over 250 AI-enabled devices authorized by the FDA by September 2025 [3] Key Companies - Intuitive Surgical (ISRG) is expected to achieve 14.3% revenue growth in 2026, driven by the demand for its da Vinci surgical systems and recent FDA clearances [10][11] - Insulet (PODD) reported over $700 million in revenues for Q3 2025, with anticipated revenue and EPS growth of 19.8% and 26.3% respectively in 2026, supported by the expansion of its Omnipod portfolio [12][13] - Boston Scientific (BSX) is projected to see revenue and EPS growth of 11.1% and 13.6% respectively in 2026, bolstered by the success of its WATCHMAN device and FARAPULSE technology [14][15] - IDEXX Laboratories (IDXX) is expected to grow revenues and EPS by 8.9% and 11.6% respectively in 2026, driven by innovations in its Companion Animal Group business [16][17] Medical Advances - Regenerative medicine is emerging as a promising field for treating various injuries and diseases, utilizing stem cells and gene editing technologies [5] - Digital Twins technology is projected to grow at a CAGR of 16.6% from 2025 to 2032, enhancing personalized treatment strategies [6] - AI-powered robotic surgery has shown a 25% reduction in operative time and a 30% decrease in intraoperative complications compared to manual methods [7]

Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s ExosomesTORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-biotechnology company developing exosome-based therapies for central nervous system injuries, today announced meaningful progress in its long-term clinical-readiness strategy. The Company has begun the process of evaluating potential Israeli production partners ...